Working closely with oncologists on value assessment frameworks can save money for the healthcare system while guaranteeing great outcomes for patients, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
Working closely with oncologists on value assessment frameworks can save money for the healthcare system while guaranteeing great outcomes for patients, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016.
Transcript (slightly modified)
Is Express Scripts using any of the value assessment frameworks to aid in formulary decision making?
We already are using value-based concepts. We actually work very close with ICER [Institute of Clinical and Economic Review], we've also been working very closely with Peter Bach, MD, and his DrugAbacus at Memorial Sloan Kettering. And so we look at, there are going to be opportunities to actually narrow formularies in oncology in the near future, which we've never had before. But it's going to take a level of sophistication and cooperation with the oncologists that we've never had before.
How are you working with oncologists to educate them about these new frameworks?
I'll be up at ASCO in just a couple of weeks. We actually view that we have got to have relationships. We've proved with hepatitis that if we have really close working relationships with the hepatologists we could get 96% cure rates and save $1 billion. We believe that same opportunity exists in oncology.
By working closer with the oncologists on care pathways, selection of drugs, introductions of biosimilars and generics for oncologic agents, we're going to be able to find areas where we can save money but also guarantee great outcomes for patients. And that really is the aim of the project.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More